177 related articles for article (PubMed ID: 36732462)
1. Docking and Molecular Dynamics Simulation Revealed the Potential Inhibitory Activity of Amygdalin in Triple-Negative Breast Cancer Therapeutics Targeting the BRCT Domain of BARD1 Receptor.
Chatterjee P; Karn R; Emerson IA; Banerjee S
Mol Biotechnol; 2024 Apr; 66(4):718-736. PubMed ID: 36732462
[TBL] [Abstract][Full Text] [Related]
2. BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing.
Zhao W; Steinfeld JB; Liang F; Chen X; Maranon DG; Jian Ma C; Kwon Y; Rao T; Wang W; Sheng C; Song X; Deng Y; Jimenez-Sainz J; Lu L; Jensen RB; Xiong Y; Kupfer GM; Wiese C; Greene EC; Sung P
Nature; 2017 Oct; 550(7676):360-365. PubMed ID: 28976962
[TBL] [Abstract][Full Text] [Related]
3. Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells.
Malka MM; Eberle J; Niedermayer K; Zlotos DP; Wiesmüller L
Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356606
[TBL] [Abstract][Full Text] [Related]
4. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
[TBL] [Abstract][Full Text] [Related]
5. Structural dynamics of clinically-reported VUS in the BARD1 ARD-BRCT region to predict the molecular basis of alterations.
Barua SA; Choudhary RK; Gawde J; Mishra N; Varma AK
J Biomol Struct Dyn; 2024 Jul; 42(11):5475-5484. PubMed ID: 37418175
[TBL] [Abstract][Full Text] [Related]
6. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
7. Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients.
De Brakeleer S; De Grève J; Desmedt C; Joris S; Sotiriou C; Piccart M; Pauwels I; Teugels E
Clin Genet; 2016 Mar; 89(3):336-40. PubMed ID: 26010302
[TBL] [Abstract][Full Text] [Related]
8. RNF168-mediated localization of BARD1 recruits the BRCA1-PALB2 complex to DNA damage.
Krais JJ; Wang Y; Patel P; Basu J; Bernhardy AJ; Johnson N
Nat Commun; 2021 Aug; 12(1):5016. PubMed ID: 34408138
[TBL] [Abstract][Full Text] [Related]
9. Is it a wrap? Nucleosome interactions of the BRCA1-binding partner, BARD1, steal the scene.
Morris JR
Nat Struct Mol Biol; 2021 Sep; 28(9):708-710. PubMed ID: 34518696
[No Abstract] [Full Text] [Related]
10. Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified in a triple-negative breast cancer patient.
Zheng Y; Li B; Pan D; Cao J; Zhang J; Wang X; Li X; Hou W; Bao D; Ren L; Yang J; Wang S; Qiu Y; Zhou F; Liu Z; Zhu S; Zhang L; Qing T; Wang Y; Yu Y; Wu J; Hu X; Shi L
Breast Cancer Res; 2021 May; 23(1):53. PubMed ID: 33933153
[TBL] [Abstract][Full Text] [Related]
11.
Rofes P; Del Valle J; Torres-Esquius S; Feliubadaló L; Stradella A; Moreno-Cabrera JM; López-Doriga A; Munté E; De Cid R; Campos O; Cuesta R; Teulé Á; Grau È; Sanz J; Capellá G; Díez O; Brunet J; Balmaña J; Lázaro C
Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33498765
[TBL] [Abstract][Full Text] [Related]
12. Racial differences in RAD51 expression are regulated by miRNA-214-5P and its inhibition synergizes with olaparib in triple-negative breast cancer.
Mani C; Acharya G; Saamarthy K; Ochola D; Mereddy S; Pruitt K; Manne U; Palle K
Breast Cancer Res; 2023 Apr; 25(1):44. PubMed ID: 37081516
[TBL] [Abstract][Full Text] [Related]
13. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
[TBL] [Abstract][Full Text] [Related]
14. Thermodynamic study of the BRCT domain of BARD1 and its interaction with the -pSER-X-X-Phe- motif-containing BRIP1 peptide.
Thanassoulas A; Nomikos M; Theodoridou M; Yannoukakos D; Mastellos D; Nounesis G
Biochim Biophys Acta; 2010 Sep; 1804(9):1908-16. PubMed ID: 20451671
[TBL] [Abstract][Full Text] [Related]
15. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
[TBL] [Abstract][Full Text] [Related]
16. Functional analysis of clinical
Toh MR; Chong ST; Chan SH; Low CE; Ishak NDB; Lim JQ; Courtney E; Ngeow J
Cold Spring Harb Mol Case Stud; 2019 Aug; 5(4):. PubMed ID: 31371347
[TBL] [Abstract][Full Text] [Related]
17. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
18. Structural basis to stabilize the domain motion of BARD1-ARD BRCT by CstF50.
Choudhary RK; Siddiqui MQ; Thapa PS; Gadewal N; Nachimuthu SK; Varma AK
Sci Rep; 2017 Jun; 7(1):3849. PubMed ID: 28634376
[TBL] [Abstract][Full Text] [Related]
19. Molecular dynamics simulations reveal the effect of mutations in the RING domains of BRCA1-BARD1 complex and its relevance to the prognosis of breast cancer.
Kiewhuo K; Priyadarsinee L; Sarma H; Sastry GN
J Biomol Struct Dyn; 2023; 41(22):12734-12752. PubMed ID: 36775657
[TBL] [Abstract][Full Text] [Related]
20. MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple‑negative breast cancer cells.
Zeng X; Jiang S; Ruan S; Guo Z; Guo J; Liu M; Ye C; Dong J
Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34080025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
